Viking Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2014 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Viking Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2014 to 2023.
  • Viking Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$36.6M, a 34.1% decline year-over-year.
  • Viking Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$134M, a 45.9% decline year-over-year.
  • Viking Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$101M, a 43.3% decline from 2022.
  • Viking Therapeutics, Inc. annual Operating Income (Loss) for 2022 was -$70.4M, a 26.4% decline from 2021.
  • Viking Therapeutics, Inc. annual Operating Income (Loss) for 2021 was -$55.7M, a 30.5% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$101M -$30.5M -43.3% Jan 1, 2023 Dec 31, 2023 10-K 2024-02-07
2022 -$70.4M -$14.7M -26.4% Jan 1, 2022 Dec 31, 2022 10-K 2024-02-07
2021 -$55.7M -$13M -30.5% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-07
2020 -$42.7M -$9.98M -30.5% Jan 1, 2020 Dec 31, 2020 10-K 2022-02-09
2019 -$32.7M -$6.53M -24.9% Jan 1, 2019 Dec 31, 2019 10-K 2021-02-17
2018 -$26.2M -$7.09M -37.2% Jan 1, 2018 Dec 31, 2018 10-K 2020-02-26
2017 -$19.1M -$5.22M -37.7% Jan 1, 2017 Dec 31, 2017 10-K 2019-03-13
2016 -$13.8M -$1.85M -15.4% Jan 1, 2016 Dec 31, 2016 10-K 2018-03-07
2015 -$12M +$11.5M +48.9% Jan 1, 2015 Dec 31, 2015 10-K 2017-03-21
2014 -$23.5M Jan 1, 2014 Dec 31, 2014 10-K 2016-03-08
* An asterisk sign (*) next to the value indicates that the value is likely invalid.